Wanbury Limited Share Price NSE India S.E.

Equities

WANBURY

INE107F01022

Pharmaceuticals

Market Closed - NSE India S.E. 05:13:56 28/06/2024 pm IST 5-day change 1st Jan Change
155.2 INR -0.70% Intraday chart for Wanbury Limited -4.88% +23.14%
Sales 2022 5.11B 61.34M Sales 2023 5B 59.96M Capitalization 1.22B 14.65M
Net income 2022 815M 9.78M Net income 2023 -104M -1.25M EV / Sales 2022 0.66 x
Net Debt 2022 583M 7M Net Debt 2023 764M 9.17M EV / Sales 2023 0.4 x
P/E ratio 2022
3.37 x
P/E ratio 2023
-11.7 x
Employees 1,582
Yield 2022 *
-
Yield 2023
-
Free-Float 43.43%
More Fundamentals * Assessed data
Dynamic Chart
1 day-0.70%
1 week-4.88%
Current month+3.97%
1 month+1.12%
3 months+9.46%
6 months+18.53%
Current year+23.14%
More quotes
1 week
153.37
Extreme 153.37
165.25
1 month
131.20
Extreme 131.2
168.50
Current year
123.00
Extreme 123
179.35
1 year
46.60
Extreme 46.6
179.35
3 years
33.30
Extreme 33.3
179.35
5 years
10.75
Extreme 10.75
179.35
10 years
10.75
Extreme 10.75
179.35
More quotes
Managers TitleAgeSince
Director of Finance/CFO - 22/16/22
Compliance Officer - 20/15/20
Members of the board TitleAgeSince
Director/Board Member 65 23/01/23
Director/Board Member 52 17/22/17
Director/Board Member - 18/11
More insiders
Date Price Change Volume
28/24/28 155.2 -0.70% 127,403
27/24/27 156.3 -1.49% 76,693
26/24/26 158.7 -1.24% 146,676
25/24/25 160.7 -0.19% 52,586
24/24/24 161 -1.90% 57,109

Delayed Quote NSE India S.E., June 28, 2024 at 05:13 pm IST

More quotes
Wanbury Limited is an India-based pharmaceutical company having a presence in active pharmaceutical ingredients (APIs) global market and domestic branded formulations. It is engaged in the business of pharmaceutical and related activities, including research. Its API products include metformin, metformin dc, tramadol, sertraline, diphenhydramine hcl, diphenhydramine citrate, mefenamic acid, paroxetine hemihydrate, promethazine, glucosamine, clopidogrel, levetiracetam and carvedilol phosphate monohydrate. In formulations, the Company has a presence across various therapeutic categories, such as cough and cold solutions, gynecology, orthopedics, nutraceuticals, gastrointestinal, anti-inflammatory and analgesics. The Company is also focused on development of products like ketamine, rivaroxaban, montelukast, sitagliptin and few others to reduce dependency on metformin and sertraline. The Company has USFDA and EUGMP approved facilities at Tanuku, Andra Pradesh, and Patalganga, Maharashtra.
More about the company